Elevation Oncology, Inc. (NASDAQ:ELEV) Receives $6.83 Average PT from Brokerages
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target […]
